WSU Researchers Develop Promising Nanotherapy for Endometriosis in Early Testing
Researchers at Washington State University have developed an experimental treatment that reduced endometriosis-related pain and disease progression in mice, offering a potential new direction for research into the chronic condition.
The targeted nanotherapy combines an existing drug with a specialized nanoparticle designed to deliver it to cells associated with endometriosis. The findings, published in Advanced Healthcare Materials, could help researchers explore treatments that target the disease more precisely.
The results are preliminary, however. The therapy has not yet been established as safe or effective in humans, and further research is needed before clinical use could be considered.
How the Experimental Treatment Works
Endometriosis occurs when tissue similar to the lining of the uterus grows elsewhere in the body, often causing inflammation, chronic pelvic pain and fertility problems. The condition affects an estimated 190 million women worldwide.
The WSU research team focused on macrophages, a type of immune cell involved in the body’s inflammatory response. Previous work by the researchers identified a distinct population of these cells associated with endometriosis, making them a potential target for treatment.
The team used niclosamide, a drug approved to treat intestinal tapeworm infections, and paired it with a nanoscale delivery system designed to direct the medication toward the targeted cells.
The approach addresses a limitation of niclosamide: the drug has low solubility, which can make it difficult to deliver effectively at suitable doses. By attaching it to a specialized nanocarrier, researchers aim to improve delivery to affected tissue while limiting exposure to other parts of the body.
The goal is to target disease-associated cells more precisely rather than relying only on treatments that affect broader hormonal or inflammatory processes.
What the Researchers Found
In experiments using a mouse model of endometriosis, the targeted treatment reduced pain-related symptoms and slowed or halted the progression of lesions after a single dose, according to Washington State University.
The researchers reported that the delivery system directed the drug toward the intended immune cells and did not show the same accumulation in other organs that could raise concerns about unwanted exposure.
These findings provide an early indication that targeted drug delivery may be worth exploring as a potential approach to endometriosis. However, results in animals do not necessarily predict how a treatment will perform in people.
Researchers will need to establish the therapy’s safety, effective dosage, durability and potential side effects through further testing before determining whether it can advance to human clinical trials.
Why New Treatment Approaches Matter
Endometriosis can cause debilitating pain, painful menstrual periods, pain during sex and infertility. Diagnosis can also take years, leaving some patients managing symptoms for long periods before receiving appropriate care.
Current treatment options include hormonal medications and surgery. Hormonal treatments can help manage symptoms but may have side effects or affect fertility while being used. Surgery can remove lesions, although symptoms or lesions may return.
The WSU research does not replace these existing options. Instead, it investigates whether a treatment aimed at specific immune cells could eventually provide another approach, potentially without relying on the same hormonal mechanisms.
For patients, the distinction is important: a promising laboratory result is an early research milestone, not evidence that a new therapy is ready to prescribe.
What Comes Next for the WSU Research
The research team, including Kanako Hayashi of WSU’s School of Molecular Biosciences in the College of Veterinary Medicine, hopes to continue developing the technology toward potential human testing.
Further work will be needed to evaluate safety and effectiveness, determine appropriate dosing and establish whether the results observed in mice can be reproduced in humans. The timeline for clinical trials and any eventual approval remains uncertain.
The study adds to ongoing efforts to better understand endometriosis and develop treatments that address its underlying biological mechanisms.
For Washington residents and the wider medical research community, the findings highlight work taking place at WSU to investigate new approaches to a condition that affects millions worldwide. The next major milestone will be determining whether this targeted nanotherapy can safely deliver similar benefits in people.